HYL — Hyloris Pharmaceuticals SA Income Statement
0.000.00%
Last trade - 00:00
- €336.00m
- €307.06m
- €2.81m
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | PRESS | PRESS |
Standards: | IFRS | IFRS | IFRS | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.091 | 0.175 | 3.1 | 1.95 | 2.81 |
Cost of Revenue | |||||
Gross Profit | 0.025 | 0.03 | 2.99 | 1.86 | 2.72 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5.37 | 7.2 | 13.6 | 13.6 | 19.1 |
Operating Profit | -5.27 | -7.03 | -10.5 | -11.6 | -16.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.78 | -7.14 | -11.3 | -11.8 | -15.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.77 | -7.15 | -11.6 | -11.8 | -15.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.77 | -7.15 | -11.6 | -11.8 | -15.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.77 | -7.14 | -11.6 | -11.8 | -15.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.02 | -0.313 | -0.448 | -0.433 | -0.58 |